1. Home
  2. GKOS vs HSBC Comparison

GKOS vs HSBC Comparison

Compare GKOS & HSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • HSBC
  • Stock Information
  • Founded
  • GKOS 1998
  • HSBC 1865
  • Country
  • GKOS United States
  • HSBC United Kingdom
  • Employees
  • GKOS N/A
  • HSBC 211000
  • Industry
  • GKOS Medical/Dental Instruments
  • HSBC Savings Institutions
  • Sector
  • GKOS Health Care
  • HSBC Finance
  • Exchange
  • GKOS Nasdaq
  • HSBC Nasdaq
  • Market Cap
  • GKOS 5.1B
  • HSBC 180.3B
  • IPO Year
  • GKOS 2015
  • HSBC N/A
  • Fundamental
  • Price
  • GKOS $90.26
  • HSBC $52.50
  • Analyst Decision
  • GKOS Strong Buy
  • HSBC Buy
  • Analyst Count
  • GKOS 13
  • HSBC 1
  • Target Price
  • GKOS $155.00
  • HSBC N/A
  • AVG Volume (30 Days)
  • GKOS 1.0M
  • HSBC 3.0M
  • Earning Date
  • GKOS 04-30-2025
  • HSBC 04-29-2025
  • Dividend Yield
  • GKOS N/A
  • HSBC 8.25%
  • EPS Growth
  • GKOS N/A
  • HSBC 8.77
  • EPS
  • GKOS N/A
  • HSBC 1.24
  • Revenue
  • GKOS $383,481,000.00
  • HSBC $61,253,000,000.00
  • Revenue This Year
  • GKOS $27.84
  • HSBC $8.82
  • Revenue Next Year
  • GKOS $27.99
  • HSBC $1.91
  • P/E Ratio
  • GKOS N/A
  • HSBC $8.04
  • Revenue Growth
  • GKOS 21.85
  • HSBC 8.70
  • 52 Week Low
  • GKOS $77.91
  • HSBC $39.42
  • 52 Week High
  • GKOS $163.71
  • HSBC $61.88
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 41.57
  • HSBC 46.48
  • Support Level
  • GKOS $86.16
  • HSBC $51.76
  • Resistance Level
  • GKOS $94.55
  • HSBC $50.04
  • Average True Range (ATR)
  • GKOS 6.54
  • HSBC 1.49
  • MACD
  • GKOS 1.11
  • HSBC -0.03
  • Stochastic Oscillator
  • GKOS 54.51
  • HSBC 55.30

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About HSBC HSBC Holdings plc.

Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in around 60 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.

Share on Social Networks: